Loading clinical trials...
Loading clinical trials...
The Impact of Rabeprazole-based Triple Therapy Plus Bismuth for First-line Helicobacter Pylori Eradication on the Vaginal Microecology Change: a Prospective, Randomized Controlled Trial
Conditions
Interventions
rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy
Locations
1
China
Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Start Date
March 24, 2023
Primary Completion Date
March 24, 2023
Completion Date
March 24, 2024
Last Updated
February 13, 2026
NCT07537634
NCT07516262
NCT07335406
NCT07179159
NCT07293910
NCT07358130
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions